Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Harnessing data science to advance radiation oncology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Using microarray-based subtyping methods for breast cancer in the era of high-throughput RNA sequencing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Brain tumor biomarkers for research, clinics, and registries - The 2021 Brain Tumor Epidemiology Consortium meeting report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pathologic Characteristics of Pregnancy-Related Meningiomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma patients.

METHODS: The study included a total of 82 recurrent glioblastoma patients treated with bevacizumab combination therapy whom were both response and biomarker evaluable. Gene expression of tumor tissue was analyzed by using a customized NanoString platform covering 800 genes. Candidate gene predictors associated with response were analyzed by multivariate logistic and Cox regression analysis.

RESULTS: Two genes were independently associated with response: Low expression of angiotensinogen (2-fold decrease in AGT; OR = 2.44; 95% CI: 1.45-4.17; P = 0.0009) and high expression of a HLA class II gene (2-fold increase in HLA-DQA1; OR = 1.22; 95% CI: 1.01-1.47; P = 0.04). These two genes were included in a model that is able predict response to bevacizumab combination therapy in clinical practice. When stratified for a validated prognostic index, the predictive model for response was significantly associated with improved overall survival.

CONCLUSION: Two genes (low angiotensinogen and high HLA-class II expression) were predictive for bevacizumab response and were included in a predictive model for response. This model can be used in clinical practice to identify patients who will benefit from bevacizumab combination therapy.

OriginalsprogEngelsk
TidsskriftMolecular Oncology
Vol/bind10
Udgave nummer8
Sider (fra-til)1160-1168
ISSN1574-7891
DOI
StatusUdgivet - okt. 2016

ID: 46495203